Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment

• DOI: 10.3389/fonc.2023.1155621
• Publication Date: 2023-04-06T05:36:16Z
• Authors: María Matamala Mo...; Gijs J. J. van Sl...; Jung-Chin Chang; Esther A. Zaal; Celia R. Berkers
• Keywords: Bortezomib; multiple myeloma; drug resistance; SDG 3 - Good Health and Well-being; Oncology; bone marrow stromal cell (BMSC); tumor microenvironment; cancer metabolism; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; fluxomics; metabolomics; RC254-282; 3. Good health

Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells in the bone marrow (BM). MM remains an incurable disease, with the majority of patients experiencing multiple relapses from different drugs. The MM tumor microenvironment (TME) and in particular bone-marrow stromal cells (BMSCs) play a crucial role in the development of drug resistance. Metabolic reprogramming is emerging as a hallmark of cancer that can potentially be exploited for cancer treatment. Recent studies show that metabolism is further adjusted in MM cells during the development of drug resistance. However, little is known about the role of BMSCs in inducing metabolic changes that are associated with drug resistance. In this Perspective, we summarize current knowledge concerning the metabolic reprogramming of MM, with a focus on those changes associated with drug resistance to the proteasome inhibitor Bortezomib (BTZ). In addition, we present proof-of-concept fluxomics (glucose isotope-tracing) and Seahorse data to show that co-culture of MM cells with BMSCs skews the metabolic phenotype of MM cells towards a drug-resistant phenotype, with increased oxidative phosphorylation (OXPHOS), serine synthesis pathway (SSP), TCA cycle and glutathione (GSH) synthesis. Given the crucial role of BMSCs in conveying drug resistance, insights into the metabolic interaction between MM and BMSCs may ultimately aid in the identification of novel metabolic targets that can be exploited for therapy.